Interventional Therapy of Head and Neck Cancer with Lipid Nanoparticle-carried Rhenium 186 Radionuclide
Interventional Therapy of Head and Neck Cancer with Lipid Nanoparticle-carried Rhenium 186 Radionuclide
复制标题
DOI：
10.1016/j.jvir.2010.02.027
复制
发表时间：
2010-08-01
影响因子：
2.9
通讯作者：
Bao, Ande
中科院分区：
文献类型：
--
作者：
French, J. Tyler;Goins, Beth;Bao, Ande
目得：通过输注泵进行对流增强输送的载药脂质纳米颗粒（即脂质体）的微创介入癌症治疗可以增加肿瘤内药物浓度和保留，同时促进整个实体瘤的广泛分布。作者研究了脂质体携带β-放射性核素治疗头颈癌的效用，通过直接瘤内输注在nukerates.MATERIALS和METHODS：四组裸鼠皮下接种人舌癌细胞。在肿瘤达到1.6 cm（3）的平均大小后，治疗组接受脂质体Re-186（Re-186）（185 MBq 15 mCi]/cm（3）肿瘤）的瘤内输注。三个对照组瘤内输注未标记的脂质体、未包封的Re-186-过氧乙酸盐或未包封的中间体Re-186化合物（Re-186-N，N-双（2-巯基-乙基]-N '，N'-二乙基-乙二胺[BMEDA]）。通过平面γ照相机成像测量Re-186活性的体内分布。结果：Re-186-脂质体组在治疗后第14天的平均肿瘤体积下降至87.7% +/-20.1%，而其他三组的平均肿瘤体积增加至395.0%-514.4%（P <0.001 vs Re-186-脂质体）。Re-186-脂质体提供了更高的Re-186活性的肿瘤内保留，导致平均肿瘤辐射吸收剂量为526.3戈伊+/- 93.3，而Re-186-过氯酸盐和Re-186-BMEDA组分别仅具有3.3戈伊+/- 1.2和13.4戈伊+/- 9.2肿瘤剂量。无全身毒性observed.CONCLUSIONS：脂质体Re-186有效地治疗头颈部癌，对流增强介入治疗后的副作用最小。这些结果表明，脂质体Re-186在肿瘤介入治疗中具有潜在的临床应用价值。
PURPOSE: Minimally invasive interventional cancer therapy with drug-carrying lipid nanoparticles (ie, liposomes) via convection-enhanced delivery by an infusion pump can increase intratumoral drug concentration and retention while facilitating broad distribution throughout solid tumors. The authors investigated the utility of liposome-carrying beta-emitting radionuclides to treat head and neck cancer by direct intratumoral infusion in nude rats.MATERIALS AND METHODS: Four groups of nude rats were subcutaneously inoculated with human tongue cancer cells. After tumors reached an average size of 1.6 cm(3), the treatment group received an intratumoral infusion of liposomal rhenium-186 (Re-186) (185 MBq 15 mCi]/cm(3) tumor). Three control groups were intratumorally infused with unlabeled liposomes, unencapsulated Re-186-perrhenate, or unencapsulated intermediate Re-186 compound (Re-186-N,N-bis(2-mercapto-ethyl]-N',N'-diethyl-ethylenediamine [BMEDA]). In vivo distribution of Re-186 activity was measured by planar gamma-Camera imaging. Tumor therapy and toxicity were assessed by tumor size, body weight, and hematology.RESULTS: Average tumor volume in the Re-186-liposome group on posttreatment day 14 decreased to 87.7% +/- 20.1%, whereas tumor volumes increased to 395.0%-514.4% on average in the other three groups (P < .001 vs Re-186-liposome). The Re-186-liposomes provided much higher intratumoral retention of Re-186 activity, resulting in an average tumor radiation absorbed dose of 526.3 Gy +/- 93.3, whereas Re-186-perrhenate and Re-186-BMEDA groups had only 3.3 Gy +/- 1.2 and 13.4 Gy +/- 9.2 tumor doses, respectively. No systemic toxicity was observed.CONCLUSIONS: Liposomal Re-186 effectively treated head and neck cancer with minimal side effects after convection-enhanced interventional delivery. These results suggest the potential of liposomal Re-186 for clinical application in interventional therapy of cancer.